IGI Logo

Astrazeneca Pharma India is currently trading at Rs. 7502.10, up by 755.65 points or 11.20% from its previous closing of Rs. 6746.45 on the BSE.

The scrip opened at Rs. 6900.00 and has touched a high and low of Rs. 7549.95 and Rs. 6873.05 respectively. So far 10136 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 7550.00 on 04-Jul-2024 and a 52 week low of Rs. 4050.15 on 21-Mar-2024.

Last one week high and low of the scrip stood at Rs. 7549.95 and Rs. 6550.00 respectively. The current market cap of the company is Rs. 18617.00 crore.

The promoters holding in the company stood at 75.00%, while Institutions and Non-Institutions held 7.79% and 17.21% respectively.

AstraZeneca Pharma India has received permission to import for sale and distribution of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) from the Central Drugs Standard Control Organisation, Directorate General of Health Services, Government of India for the below mentioned additional indication:

Durvalumab (IMFINZI) in combination with chemotherapy as neoadjuvant treatment, followed by IMFINZI as monotherapy after surgery, is indicated for the treatment of patients with resectable (tumours 4 cm and/or node positive) NSCLC and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements.

The receipt of this permission paves way for the launch of Durvalumab 120 mg/2.4 mL and 500 mg/10 mL solution for infusion (Imfinzi) in India for the specified additional indication, subject to the receipt of related statutory approvals, if any.

AstraZeneca Pharma India is a global biopharmaceutical company. The company is engaged in the discovery, development and commercialization of medicines for core areas of healthcare, including cardiovascular/metabolic disease, cancer and respiratory, inflammatory and autoimmune disease. The company operates through two segments Healthcare and Clinical Trial.